» Articles » PMID: 35255093

Pan-ebolavirus Serology Study of Healthcare Workers in the Mbandaka Health Region, Democratic Republic of the Congo

Abstract

Although multiple antigenically distinct ebolavirus species can cause human disease, previous serosurveys focused on only Zaire ebolavirus (EBOV). Thus, the extent of reactivity or exposure to other ebolaviruses, and which sociodemographic factors are linked to this seroreactivity, are unclear. We conducted a serosurvey of 539 healthcare workers (HCW) in Mbandaka, Democratic Republic of the Congo, using ELISA-based analysis of serum IgG against EBOV, Sudan ebolavirus (SUDV) and Bundibugyo ebolavirus (BDBV) glycoproteins (GP). We compared seroreactivity to risk factors for viral exposure using univariate and multivariable logistic regression. Seroreactivity against different GPs ranged from 2.2-4.6%. Samples from six individuals reacted to all three species of ebolavirus and 27 samples showed a species-specific IgG response. We find that community health volunteers are more likely to be seroreactive against each antigen than nurses, and in general, that HCWs with indirect patient contact have higher anti-EBOV GP IgG levels than those with direct contact. Seroreactivity against ebolavirus GP may be associated with positions that offer less occupational training and access to PPE. Those individuals with broadly reactive responses may have had multiple ebolavirus exposures or developed cross-reactive antibodies. In contrast, those individuals with species-specific BDBV or SUDV GP seroreactivity may have been exposed to an ebolavirus not previously known to circulate in the region.

Citing Articles

Seroprevalence of Antibodies to Filoviruses with Outbreak Potential in Sub-Saharan Africa: A Systematic Review to Inform Vaccine Development and Deployment.

Semancik C, Whitworth H, Price M, Yun H, Postler T, Zaric M Vaccines (Basel). 2025; 12(12.

PMID: 39772055 PMC: 11726543. DOI: 10.3390/vaccines12121394.


Low seroprevalence of Ebola virus in health care providers in an endemic region (Tshuapa province) of the Democratic Republic of the Congo.

Zola Matuvanga T, Marien J, Lariviere Y, Isekah Osangir B, Milolo S, Meta R PLoS One. 2023; 18(9):e0286479.

PMID: 37656725 PMC: 10473486. DOI: 10.1371/journal.pone.0286479.


The rVSV-EBOV vaccine provides limited cross-protection against Sudan virus in guinea pigs.

Cao W, He S, Liu G, Schulz H, Emeterio K, Chan M NPJ Vaccines. 2023; 8(1):91.

PMID: 37301890 PMC: 10257645. DOI: 10.1038/s41541-023-00685-z.


Molecular adaptations during viral epidemics.

Rochman N, Wolf Y, Koonin E EMBO Rep. 2022; 23(8):e55393.

PMID: 35848484 PMC: 9346483. DOI: 10.15252/embr.202255393.


Epitope-focused immunogen design based on the ebolavirus glycoprotein HR2-MPER region.

Schoeder C, Gilchuk P, Sangha A, Ledwitch K, Malherbe D, Zhang X PLoS Pathog. 2022; 18(5):e1010518.

PMID: 35584193 PMC: 9170092. DOI: 10.1371/journal.ppat.1010518.

References
1.
Lucas A, Kumakamba C, Lange C, Obel E, Miningue G, Likofata J . Serology and Behavioral Perspectives on Ebola Virus Disease Among Bushmeat Vendors in Equateur, Democratic Republic of the Congo, After the 2018 Outbreak. Open Forum Infect Dis. 2020; 7(8):ofaa295. PMC: 7443109. DOI: 10.1093/ofid/ofaa295. View

2.
Wong G, He S, Wei H, Kroeker A, Audet J, Leung A . Development and Characterization of a Guinea Pig-Adapted Sudan Virus. J Virol. 2015; 90(1):392-9. PMC: 4702555. DOI: 10.1128/JVI.02331-15. View

3.
Bornholdt Z, Turner H, Murin C, Li W, Sok D, Souders C . Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak. Science. 2016; 351(6277):1078-83. PMC: 4900763. DOI: 10.1126/science.aad5788. View

4.
Doshi R, Hoff N, Bratcher A, Mukadi P, Gadoth A, Nicholson B . Risk Factors for Ebola Exposure in Health Care Workers in Boende, Tshuapa Province, Democratic Republic of the Congo. J Infect Dis. 2020; 226(4):608-615. PMC: 9441197. DOI: 10.1093/infdis/jiaa747. View

5.
Mbala-Kingebeni P, Pratt C, Mutafali-Ruffin M, Pauthner M, Bile F, Nkuba-Ndaye A . Ebola Virus Transmission Initiated by Relapse of Systemic Ebola Virus Disease. N Engl J Med. 2021; 384(13):1240-1247. PMC: 7888312. DOI: 10.1056/NEJMoa2024670. View